--- title: "Weekly Recap | Beigene +9.89%, earnings beat and guidance raised" type: "News" locale: "en" url: "https://longbridge.com/en/news/304724293.md" description: "Beigene (ONC) added 9.89% this week to close at $406.96, outperforming the S&P 500 by roughly 12.57 percentage points. Trading was volatile, with a 17.27% intraday range. The stock opened lower on Monday, dipped to $347.61 on Tuesday before recovering, gapped up over 6% on Wednesday, pulled back on Thursday, and pushed to a weekly high of $410.71 on Friday, closing within cents of that level." datetime: "2026-11-07T08:36:22.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/304724293.md) - [en](https://longbridge.com/en/news/304724293.md) - [zh-HK](https://longbridge.com/zh-HK/news/304724293.md) generator: "portal-rs" --- # Weekly Recap | Beigene +9.89%, earnings beat and guidance raised ## The Week Beigene (ONC) added 9.89% this week to close at $406.96, outperforming the S&P 500 by roughly 12.57 percentage points. Trading was volatile, with a 17.27% intraday range. The stock opened lower on Monday, dipped to $347.61 on Tuesday before recovering, gapped up over 6% on Wednesday, pulled back on Thursday, and pushed to a weekly high of $410.71 on Friday, closing within cents of that level. ## Key Events On Wednesday, the U.S. Food and Drug Administration granted priority review to Brukinsa combination therapy for first-line mantle cell lymphoma, lifting the stock more than 5% in pre-market trading. On Thursday evening, Beigene reported Q3 fiscal 2026 revenue of $1.89 billion, up 34% year-on-year, with net income of $384.71 million more than tripling. Adjusted net profit for the first three quarters reached about $1.358 billion, up 96%. The company raised full-year revenue guidance to $6.9 billion to $7 billion, the third increase this year. The stock set a 52-week high in overnight trading on Friday, with UBS lifting its price target to $529 and UOB Kay Hian raising its target to HK$300. ## Analyst Ratings Among 27 institutions covering the stock, 19 rate it buy, 7 rate it overweight, and 1 rates it hold; none assign underweight or sell. The consensus rating is strong buy, with a consensus target price of $437.571, about 7.52% above the current price. Target prices range from $385 to $528, a spread of roughly 37%, suggesting meaningful disagreement on valuation. Within the biotech sector, the stock ranks 11th out of 510 names. ## The Week Ahead The market’s main focus next week shifts to U.S. CPI and core CPI data due on November 10. Headline CPI has a prior reading of 3.7% and a forecast of 3.9%, while core CPI has a prior of 2.6% and a forecast of 2.8%. On the company side, Beigene’s FY2026 annual results are scheduled for pre-market release on March 25, 2027, with consensus estimates of $7.5814 EPS and $6.762 billion revenue. Nearer term, further updates on the FDA priority review and progress toward the raised revenue guidance are the two threads to monitor. ## In Short Beigene’s week was shaped by a combination of earnings delivery and regulatory progress, producing a near 10% gain and a close within touching distance of the weekly high. The analyst backdrop leans positive, with consensus target above spot, but the target range is wide and valuation has climbed to around 50 times earnings. The latest session’s money flows show no clear single-direction dominance across small and medium orders. What matters from here is the pace of the priority review, how the raised guidance tracks against actuals, and how next week’s CPI print shifts risk appetite across the market. *This article is generated by LongbridgeAI from market data, for information only and not investment advice.* ### Related Stocks - [ONC.US](https://longbridge.com/en/quote/ONC.US.md) ## Related News & Research - [Why BeOne Medicines Stock Is In Focus After Earnings Beat And Raised Guidance](https://longbridge.com/en/news/304730912.md) - [BeOne Medicines (ONC) Gets FDA Priority Review For First Line Lymphoma Regimen](https://longbridge.com/en/news/304614462.md) - [FDA Grants Priority Review to BeOne’s Brukinsa Combination for First-Line Mantle Cell Lymphoma](https://longbridge.com/en/news/304291763.md) - [Wells Fargo maintains BeOne Medicines at Overweight, raises price target to $435 from $400](https://longbridge.com/en/news/304659494.md) - [BeOne Medicines (ONC) Priority Review And Earnings Put Valuation Back In Focus](https://longbridge.com/en/news/304861942.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**